Amicus Therapeutics, Inc. logo

FOLD

Amicus Therapeutics, Inc.

$10.14

Earnings Summary

Revenue
$110.4Mn
Net Profits
$-48.42Mn
Net Profit Margins
-43.86%

Highlights

Revenue:

Amicus Therapeutics, Inc.’s revenue jumped 27.97% since last year same period to $110.4Mn in the Q1 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated -4.07% fall in its revenue since last 3-months.

Net Profits:

Amicus Therapeutics, Inc.’s net profit jumped 8.53% since last year same period to $-48.42Mn in the Q1 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated -43.07% fall in its net profits since last 3-months.

Net Profit Margins:

Amicus Therapeutics, Inc.’s net profit margin jumped 28.52% since last year same period to -43.86% in the Q1 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated -49.13% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Amicus Therapeutics, Inc. post its latest quarter earnings

EPS Estimate Current Year
-0.07

Highlights

EPS Estimate Current Year:

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.07.

Key Ratios

Key ratios of the Amicus Therapeutics, Inc. post its Q1 2024 earnings

Earning Per Share (EPS)
-0.16
Return on Assets (ROA)
-0.05
Return on Equity (ROE)
-1.26

Highlights

Earning Per Share (EPS):

Amicus Therapeutics, Inc.’s earning per share (EPS) jumped 11.11% since last year same period to -0.16 in the Q1 2024. This indicates that the Amicus Therapeutics, Inc. has generated 11.11% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Amicus Therapeutics, Inc.’s return on assets (ROA) stands at -0.05.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Amicus Therapeutics, Inc.’s return on equity (ROE) stands at -1.26.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-05-09
-0.07
-0.16
-128.57%